For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Humana Inc.HUM US · Health Care · USD Current price$394.36as of Nov 20, 2026 Summary
Analyst consensusStrong Buy 5Buy 13Hold 7Sell 124 analysts 3-year price (USD)Factor profileMulti-factor score 75 / 100 Market data
Business descriptionLarge U.S. managed care organization focused on Medicare Advantage (second-largest MA plan, about 5.8M members at year-end 2025, about 81% of premium revenue), plus group, military (TRICARE) and Medicaid (about 12% of premiums) and a large PBM/provider-integration arm. Sub-industry: Managed Health Care; S&P 500, Large-Cap Value. Competitive moatScale in MA plus integrated pharmacy (PBM) and provider assets help contain medical costs. Star ratings are the moat lever: 2028 Stars reached a member-weighted 4.17, near the company's best ever, and CMS Stars reform (11 components removed) is seen as about a USD 5B tailwind for MA insurers in 2028. Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Nov 13, 2026
Current price: $394.36 · Nov 20, 2026· USD
CFRA Ratinghold
TBI Multi Score75
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: HUMBusiness description
Large U.S. managed care organization focused on Medicare Advantage (second-largest MA plan, about 5.8M members at year-end 2025, about 81% of premium revenue), plus group, military (TRICARE) and Medicaid (about 12% of premiums) and a large PBM/provider-integration arm. Sub-industry: Managed Health Care; S&P 500, Large-Cap Value.
Competitive moat
Scale in MA plus integrated pharmacy (PBM) and provider assets help contain medical costs. Star ratings are the moat lever: 2028 Stars reached a member-weighted 4.17, near the company's best ever, and CMS Stars reform (11 components removed) is seen as about a USD 5B tailwind for MA insurers in 2028.
Recent developments
- Q3 2026 (11/06/2026): better than expected, swung to an adjusted loss on seasonality but 2026 EPS guidance raised. Early annual enrollment ahead of plan; 2027 membership now seen up Y/Y (previously flat to down) with strong retention from exited plans.
- Management expects core medical cost trend to accelerate to 8-9% in 2027 (7-8% in 2026), driven by Medicare Part D.
- CMS final 2027 MA rate notice +2.48% (vs 0.09% proposed) on 04/07/2026 - positive for MA exposure.
- Sector read: see Managed Health Care Q3 2026 Earnings & Post-Midterm Policy; CFRA sub-industry outlook upgraded to neutral from negative.
Investment risks / red flags
- Highest MA exposure in the group: utilization, MA competition and regulatory changes hit directly.
- Valuation already reflects the recovery (46x 2026E operating EPS); CFRA sees limited upside at the current price.
- OBBBA Medicaid cuts are a headwind, but HUM has the second-lowest Medicaid exposure among peers.
Market Data
Source: mkts.io · Nov 20, 2026, 16:01 UTC
Key Metrics
P/E (TTM)38.47
P/E (Fwd)21.30
Dividend0.93%
Beta0.64
52W High$462.87
52W Low$163.11
Analyst Consensus
5
13
7
Strong Buy5Buy13Hold7Sell124 analysts
Consensus Target$508.54
+29.0% upside
Calendar Events
Next EarningsNov 6, 2026
Ex-DividendDec 24, 2026
Dividend DateJan 29, 2027
Financials
Revenue$154.19B
Rev Growth26.10%
Earnings Growth-17.90%
Gross Margin13.01%
Op Margin1.82%
Profit Margin0.81%
EBITDA$3.04B
ROA3.28%
ROE6.74%
Rev/Share$1.28K
Total Cash$25.11B
Total Debt$13.37B
D/E Ratio70.81
Free Cash Flow$3.29B
Op Cash Flow$3.73B
Current Ratio1.65
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | -7.58 | $41.40B |
| +1q | 13.43 | $43.23B |
| 0y | 9.58 | $162.89B |
| +1y | 18.62 | $173.95B |
Earnings
Quarterly EPS
4Q2025
Est: -3.99-3.96Beat
1Q2026
Est: 10.2010.31Beat
2Q2026
Est: 7.007.61Beat
3Q2026
Est: -1.00-0.70Beat
Annual
2022
Rev $92.87BEarn $2.81B
2023
Rev $106.37BEarn $2.49B
2024
Rev $117.76BEarn $1.21B
2025
Rev $129.66BEarn $1.19B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Nov 12, 2026 | Wells Fargo | main | Overweight |
| Nov 11, 2026 | TD Cowen | main | Hold |
| Nov 10, 2026 | JP Morgan | main | Neutral |
| Nov 9, 2026 | Piper Sandler | main | Overweight |
| Nov 9, 2026 | Guggenheim | main | Buy |
| Nov 9, 2026 | Barclays | main | Overweight |
